Funding for this research was provided by:
Lundbeckfonden (R260-2017-1247, R118-A11472, R296-2018-2502)
Scleroseforeningen (R487-A33600-B15690, R458-A31829-B15690)
Jascha Fonden (5589)
Direktør Ejnar Jonasson Kaldet Johnsen og Hustrus Mindelegat (5609)
Odense Universitetshospital (29A-1501)
Sanofi Genzyme (REG-NOBA-COMPL-SD-017)
Villum Fonden (Young Investigator grant nr. 13154)
Horizon 2020 (777111 (REPOTRIAL).)
Region Syddanmark (14/24200)
Received: 14 October 2019
Accepted: 25 November 2019
First Online: 11 December 2019
Ethics approval and consent to participate
: MS and control tissue samples were supplied by the UK Multiple Sclerosis Tissue Bank (UK Multicentre Research Ethics Committee, MREC/02/2/39), funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland (registered charity 207,495).
: Not applicable.
: Dr. Illes reports personal fees from Biogen, personal fees from Sanofi-Genzyme, personal fees from Merck, personal fees from Novartis, outside the submitted work.The other authors declare that they have no competing interests.